HC Wainwright & Co. Reiterates Buy on Biogen, Maintains $325 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Biogen (NASDAQ:BIIB) and maintained a $325 price target on the stock.
February 14, 2024 | 11:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein reiterated a Buy rating on Biogen with a $325 price target.
The reiteration of a Buy rating and maintenance of a $325 price target by a reputable analyst could positively influence investor sentiment towards Biogen, potentially leading to a short-term increase in its stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100